% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • hbomb57108 hbomb57108 Mar 8, 2013 5:38 PM Flag

    Cabo plus Abiraterone late breaker

    Anyone know how to pull up AACR late breaker abstract titles on AACR site. Apparently Cabo plus Abiraterone is a late breaker.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Biobetter spotted what looks to be 2 more cabo late breakers. I'm a little surprised that CRADA hasn't developed a Colon cancer study, but I guess we have some preclinical work on that indication.

      Presentation Title: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib

      Author Block: Malcolm Smith, Min Kang, Patrick Reynolds, Richard Gorlick, Anders Kolb, John Maris, Stephen Keir, Catherine Billups, Raushan Kurmasheva, Peter Houghton. National Cancer Institute, Bethesda, MD, Texas Tech University Health Sciences Center, Lubbock, TX, Montefiore Medical Center, Bronx, NY, A.I. duPont Hospital for Children, Wilmington, DE, Children’s Hospital Philadelphia, Philadelphia, PA, Duke University Medical Center, Durham, NC, St. Jude Children’s Research Hospital, Memphis, TN, Nationwide Children's Hosp. Ctr. for Childhood Cancer, Columbus, OH
      Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models

      Author Block: Chloe E. Atreya, Eun-Kee Song, Wells Messersmith, Alicia Purkey, Stacey Bagby, Kevin Quackenbush, Robin K. Kelley, Eunice Kwak, David Ryan, Alan Venook, John J. Arcaroli. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Univ. of Colorado Denver, Aurora, CO, Massachusetts General Hospital and Harvard Medical School, Boston, MA

    • OK, I found it. LB-166

      Abstract Number: LB-166
      Presentation Title: Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study.
      Location: Hall A-C, Poster Section 47
      Author Block: Christopher J. Sweeney, Katherine Zukotynski, Xiaodong Wang, Andrew Wick, Amanda Fredericks, Bon Lam, Philip Kantoff. Dana Farber Cancer Inst., Boston, MA

4.24-0.01(-0.24%)Feb 9 4:00 PMEST